BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Zelensky confidant dismissed from further posts amid bribery scandal - 2Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- 3Investigating Design and Individual Style: Track down Your Remarkable Look
- 4The Most Astonishing Arising Advances to Watch
- 5Thousands of ultra-orthodox protest in Jerusalem against conscription
- Top 20 Style Brands for Pioneers
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- Select Your Definitive Pizza Decision
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- People are getting their news from AI – and it’s altering their views
- Astounding Treehouses All over the Planet
- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- Unpaid caregiving work can feel small and personal, but that doesn’t take away its ethical value
